ClinicalTrials.gg
CompletedNCT01786382Updated Mar 26, 2013

A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole

A Phase 1 interventional study of PPI-668 and Midazolam in Pharmacokinetic Assessments in Healthy Volunteers, sponsored by Presidio Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-03-26.

Sponsored by Presidio Pharmaceuticals, Inc. · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The primary objectives of the study are to:

  • Evaluate the potential effects of PPI-668 at steady state on the pharmacokinetic (PK) profile of midazolam following a single oral dose in human subjects.
  • Evaluate the potential effects of PPI-668 at steady state on the PK profile of omeprazole following a single oral dose in human subject
02

Conditions studied

  • Pharmacokinetic Assessments in Healthy Volunteers
03

In context

Lead sponsor

Presidio Pharmaceuticals, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject or legally authorized representative signs an Institutional Review Board (IRB)-approved written and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act [HIPAA] authorization for sites in the United States) before any study-related procedures (including withdrawal of prohibited medication, if applicable) are performed
  2. Age 18 to 50 years
  3. (BMI) 18-32 kg/m2
  4. Clinical and laboratory findings consistent with good health in the opinion of the investigator
  5. Women of non- or men who agree to utilize adequate throughout the study

    1. Women of non-childbearing potential must be one of the following:

      • (>2 years amenorrhea and postmenopausal status confirmed by follicle-stimulating hormone levels)
      • Surgically sterile (documentation of prior tubal ligation, hysterectomy, or oophorectomy is required)
    2. Male subjects who are not surgically sterile must agree to use one of the following birth control methods if sexually active:

      • Double-barrier contraceptive (e.g., condom plus diaphragm, condom or diaphragm with spermicidal gel/foam)
      • Female partner is at least two years postmenopausal or surgically sterile

Exclusion criteria

Exclusion Criteria:

  1. Positive results on any of the following tests at Screening or Day -1:

    urine pregnancy (women only), urine drugs of abuse and alcohol, surface antigen, antibody, and antibody

  2. Concurrent medical diagnosis that would potentially interfere with the subject's study compliance or confound the study results
  3. Concurrent social conditions (e.g., drug or alcohol abuse, transportation difficulties) that would potentially interfere with the subject's study compliance
  4. Clinically significant illness within 30 days preceding entry into the study
  5. Participation in an drug study within 30 days or 5 half-lives, whichever is longer, before Screening
  6. Use of prescription medications within 14 days before Day 1 and throughout the study. (The use of non-prescription or over-the-counter medications is prohibited within 7 days before Day 1 and throughout the study. This includes all herbal supplements or remedies and vitamins.)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    midazolam

    potential effects of PPI-668 on midazolam pharmacokinetics

    Drug: PPI-668 · Drug: Midazolam

  • Experimental
    omeprazole

    potential effects of PPI-668 on omeprazole pharmacokinetics

    Drug: PPI-668 · Drug: Omeprazole

  • Experimental
    telaprevir

    potential effects of PPI-668 on telaprevir pharmacokinetics

    Drug: PPI-668 · Drug: Telaprevir

Interventions

06

What researchers measure

Primary outcomes

  1. Midazolam area under the plasma concentration-time curve from time 0 to 24 hours after dosing (AUC0-24)

    Time frame: Days 1-6

  2. Midazolam maximum observed plasma concentration (Cmax)

    Time frame: Days 1-6

  3. Omeprazole area under the plasma concentration-time curve from time 0 to 24 hours after dosing (AUC0-24)

    Time frame: Days 1-6

  4. Omeprazole maximum observed plasma concentration (Cmax)

    Time frame: Days 1-6

Secondary outcomes

  1. Telaprevir area under the plasma concentration-time curve from time 0 to 24 hours after dosing (AUC0-24)

    Time frame: Days 1-12

  2. Telaprevir maximum observed plasma concentration (Cmax)

    Time frame: Days 1-12

07

Study locations

1 site
  • Spaulding Clinical Research
    West Bend, Wisconsin 53095, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2013
First posted
Feb 8, 2013
Start
Feb 2013
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Last update
Mar 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01786382
Lead sponsor
Presidio Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Feb 8, 2013
Start date
Feb 2013
Primary completion
Mar 2013
Completion
Mar 2013
Last update
Mar 26, 2013

Study contacts

Paul Rice, MD
principal investigator · Spaulding Clinical

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ravidasvir · Telaprevir

Start the discussion